文献速递消化系统肿瘤

FOLFIRI联合雷莫西尤单抗对比FOLFOXIRI联合雷莫西尤单抗一线治疗转移性结直肠癌的随机II期研究

Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST).
PubMed 文献 · Eur J Cancer · 2026-03-19

WJOG9216G(RECAST)是一项随机II期研究,比较FOLFIRI-RAM与FOLFOXIRI-RAM一线治疗初治转移性结直肠癌的疗效与安全性,共随机122例。主要终点确认客观缓解率两组分别为59.3%和60.3%(OR=1.04,P=0.91),无进展生存期相当;FOLFIRI-RAM组早期肿瘤退缩率和总生存期显著更优,且≥3级不良事件发生率更低。

要点

  • FOLFOXIRI-RAM在客观缓解率上不优于FOLFIRI-RAM(59.3% vs 60.3%,P=0.91)。
  • FOLFIRI-RAM组早期肿瘤退缩率(71.2% vs 52.4%)和总生存期(中位32.6 vs 28.2个月)显著更优。
  • FOLFIRI-RAM组≥3级中性粒细胞减少(44.1% vs 72.6%)和发热性中性粒细胞减少(3.4% vs 11.3%)更低。

核心结论

  • 在初治转移性结直肠癌患者中,FOLFOXIRI联合雷莫西尤单抗在包括客观缓解率在内的疗效方面不优于FOLFIRI联合雷莫西尤单抗。
  • 一线FOLFIRI联合雷莫西尤单抗显示出与双药化疗联合贝伐珠单抗相当的临床疗效和安全性特征。

研究设计与样本

  • 随机II期研究(WJOG9216G,RECAST),将初治转移性结直肠癌患者随机分配至FOLFIRI-RAM组或FOLFOXIRI-RAM组,共122例。
  • 主要终点为确认的客观缓解率,次要终点包括早期肿瘤退缩、无进展生存期、总生存期和安全性。

主要发现

  • 确认的客观缓解率在FOLFIRI-RAM组和FOLFOXIRI-RAM组分别为59.3%和60.3%(比值比1.04;P=0.91)。
  • 中位随访时间分别为42.1个月和40.4个月,无进展生存期两组相当(中位11.5个月和10.5个月)。
  • 早期肿瘤退缩率(71.2%和52.4%)和总生存期(中位32.6个月和28.2个月)在FOLFIRI-RAM组显著优于FOLFOXIRI-RAM组。
  • FOLFIRI-RAM组和FOLFOXIRI-RAM组主要≥3级不良事件为中性粒细胞减少(44.1%和72.6%)、厌食(3.4%和14.5%)和发热性中性粒细胞减少(3.4%和11.3%)。

临床怎么用

  • 对于初治转移性结直肠癌,FOLFIRI联合雷莫西尤单抗可作为一线治疗选择,其疗效和安全性可能与双药化疗联合贝伐珠单抗相当。
  • FOLFOXIRI联合雷莫西尤单抗未显示优于FOLFIRI联合雷莫西尤单抗,且≥3级不良事件发生率更高,选择时需权衡获益与毒性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: FOLFOXIRI plus bevacizumab improved efficacies and increased some adverse events in untreated metastatic colorectal cancer (mCRC), compared with the doublet plus bevacizumab. The clinical outcomes of ramucirumab (RAM) in combination with FOLFIRI or FOLFOXIRI as a first-line treatment are unknown. In this randomized phase II study (WJOG9216G), we compared the efficacy and safety of these regimens to determine which is more promising. METHODS: Patients with untreated mCRC were randomly assigned to the FOLFIRI-RAM or FOLFOXIRI-RAM arms. The primary endpoint was a confirmed objective response rate (ORR), and secondary endpoints included early tumor shrinkage (ETS), progression-free survival (PFS), overall survival (OS), and safety. RESULTS: In total, 122 patients were randomized. The confirmed ORR was 59.3% and 60.3% in the FOLFIRI-RAM and FOLFOXIRI-RAM arms, respectively (odds ratio 1.04; P = 0.91). With a median follow-up period of 42.1 and 40.4 months, PFS was comparable between the FOLFIRI-RAM and FOLFOXIRI-RAM arms (median, 11.5 and 10.5 months). ETS rate (71.2% and 52.4%) and OS (median, 32.6 and 28.2 months) were significantly better in the FOLFIRI-RAM arm than in the FOLFOXIRI-RAM arm. The major grade ≥ 3 adverse events in the FOLFIRI-RAM and FOLFOXIRI-RAM arms were neutropenia (44.1% and 72.6%), anorexia (3.4% and 14.5%), and febrile neutropenia (3.4% and 11.3%). CONCLUSIONS: FOLFOXIRI plus RAM was not superior to FOLFIRI plus RAM in terms of efficacy, including ORR, in patients with untreated mCRC. Instead, first-line FOLFIRI plus RAM showed clinical efficacy and safety profiles comparable to those of doublet chemotherapy plus bevacizumab.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Kito Y, Yamazaki K, Shoji H, et al. Randomized phase II study of FOLFIRI plus ramucirumab versus FOLFOXIRI plus ramucirumab as first-line treatment for metastatic colorectal cancer: WJOG9216G (RECAST). Eur J Cancer. 2026. PMID: 41880871. doi:10.1016/j.ejca.2026.116688

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。